MAP2K1 Q56P

CI-VAR-00003553Explore in graph →NP_002746.1:p.Gln56ProNM_002755.3:c.167A>CClinVar 375978 CIViC 83 rs1057519729

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Melanoma2
MAP2K1 Q56P	Selumetinib	Predictive	D	Supports Resistance	3	accepted	EID13 A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expres… (full text at CIViC) PMID 19915144 · Emery et al., 2009 · Open in CIViC	civic
MAP2K1 Q56P	Vemurafenib	Predictive	C	Supports Resistance	—	submitted	EID4727 In a retrospective study of a phase 2 clinical trial (NCT00949702), of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, the MAP2K1 Q56P mutation was associ… (full text at CIViC) PMID 23569304 · Trunzer et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
375978	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Non-small cell lung carcinoma; Melorheostosis; Neoplasm; Extracranial arteriovenous malformation	germline/somatic	5	May 15, 2024	clinvar